2023
Taieb, J., Seufferlein, T., Reni, M., Palmer, D. H., Bridgewater, J. A., Cubillo, A., . . . Macarulla, T. (2023). Treatment sequences and prognostic/predictive factors in metastatic pancreatic ductal adenocarcinoma: univariate and multivariate analyses of a real-world study in Europe. BMC CANCER, 23(1). doi:10.1186/s12885-023-11377-1DOI: 10.1186/s12885-023-11377-1
Quinn, L. M., Haldenby, S., Antzcak, P., Fowler, A., Bullock, K., Kenny, J., . . . Goldring, C. (n.d.). Genomic profiling of idiopathic peri-hilar cholangiocarcinoma reveals new targets and mutational pathways. Scientific Reports, 13(1). doi:10.1038/s41598-023-33096-0DOI: 10.1038/s41598-023-33096-0
PINCER (A Platform Study for solId orgaN CancERs): an agile pan-network platform study to deliver high-quality translational research (Journal article)
Jones, R. P., Mielgo, A., Schmid, M., Bury, D., Andrews, T., Burdak-Rothkamm, S., . . . Vimalachandran, D. (2023). PINCER (A Platform Study for solId orgaN CancERs): an agile pan-network platform study to deliver high-quality translational research. BRITISH JOURNAL OF SURGERY. doi:10.1093/bjs/znad097DOI: 10.1093/bjs/znad097
Ahmed, A. A., Greenhalf, W., Palmer, D. H., Williams, N., Worthington, J., Arshad, T., . . . Neidle, S. (2023). The Potent G-Quadruplex-Binding Compound QN-302 Downregulates S100P Gene Expression in Cells and in an In Vivo Model of Pancreatic Cancer. MOLECULES, 28(6). doi:10.3390/molecules28062452DOI: 10.3390/molecules28062452
de Andres, M. P., Jackson, R. J., Felipe, I., Zagorac, S., Pilarsky, C., Schlitter, A. M., . . . Real, F. X. (2023). GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinoma. GUT, 72(3), 535-548. doi:10.1136/gutjnl-2021-325803DOI: 10.1136/gutjnl-2021-325803
Kudo, M., Finn, R. S., Qin, S., Han, K. -H., Ikeda, K., Cheng, A. -L., . . . Lencioni, R. (2023). Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study.. Journal of hepatology, 78(1), 133-141. doi:10.1016/j.jhep.2022.09.006DOI: 10.1016/j.jhep.2022.09.006
Hydes, T. J., Cuthbertson, D. J., Palmer, D. H., Elshaarawy, O., Johnson, P. J., Fernando, R., & Cross, T. J. (2023). Ultrasonography in surveillance for hepatocellular carcinoma in patients with non-alcoholic fatty liver disease. HEPATOMA RESEARCH, 9. doi:10.20517/2394-5079.2022.97DOI: 10.20517/2394-5079.2022.97
2022
Ghaneh, P., Palmer, D., Cicconi, S., Jackson, R., Halloran, C. M., Rawcliffe, C., . . . European Study Group for Pancreatic Cancer. (2022). Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial.. The lancet. Gastroenterology & hepatology, S2468-1253(22)00348-X. doi:10.1016/s2468-1253(22)00348-xDOI: 10.1016/s2468-1253(22)00348-x
Oldfield, L., Stott, M., Hanson, R., Jackson, R. J., Reynolds, W., Chandran-Gorner, V., . . . Costello, E. (2022). United Kingdom Early Detection Initiative (UK-EDI): protocol for establishing a national multicentre cohort of individuals with new-onset diabetes for early detection of pancreatic cancer. BMJ OPEN, 12(10). doi:10.1136/bmjopen-2022-068010DOI: 10.1136/bmjopen-2022-068010
Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study (Journal article)
Bridgewater, J., Fletcher, P., Palmer, D. H., Malik, H. Z., Prasad, R., Mirza, D., . . . Primrose, J. (2022). Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study. JOURNAL OF CLINICAL ONCOLOGY, 40(18), 2048-+. doi:10.1200/JCO.21.02568DOI: 10.1200/JCO.21.02568
Verset, G., Borbath, I., Karwal, M., Verslype, C., Van Vlierberghe, H., Kardosh, A., . . . Zhu, A. X. (2022). Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial. CLINICAL CANCER RESEARCH, 28(12), 2547-2554. doi:10.1158/1078-0432.CCR-21-3807DOI: 10.1158/1078-0432.CCR-21-3807
Rai, Z. L., Ranieri, V., Palmer, D. H., Littler, P., Ghaneh, P., Gurusamy, K., . . . Davidson, B. R. (2022). Treatment of unresectable locally advanced pancreatic cancer with percutaneous irreversible electroporation (IRE) following initial systemic chemotherapy (LAP-PIE) trial: study protocol for a feasibility randomised controlled trial. BMJ OPEN, 12(5). doi:10.1136/bmjopen-2021-050166DOI: 10.1136/bmjopen-2021-050166
Major variation in hepatocellular carcinoma treatment and outcomes in England: a retrospective cohort study. (Journal article)
Beecroft, S., O'Connell, M., Nassar, A., Noon, K., Pollock, K. G., Palmer, D., & Cross, T. J. S. (2023). Major variation in hepatocellular carcinoma treatment and outcomes in England: a retrospective cohort study.. Frontline gastroenterology, 14(1), 19-24. doi:10.1136/flgastro-2022-102142DOI: 10.1136/flgastro-2022-102142
Kudo, M., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D. H., . . . Zhu, A. X. (2022). Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. EUROPEAN JOURNAL OF CANCER, 167, 1-12. doi:10.1016/j.ejca.2022.02.009DOI: 10.1016/j.ejca.2022.02.009
Burton, A., Balachandrakumar, V. K., Driver, R. J., Tataru, D., Paley, L., Marshall, A., . . . Cross, T. J. S. (2022). Regional variations in hepatocellular carcinoma incidence, routes to diagnosis, treatment and survival in England. BRITISH JOURNAL OF CANCER, 126(5), 804-814. doi:10.1038/s41416-021-01509-4DOI: 10.1038/s41416-021-01509-4
Efficacy and Safety Results from a Phase 2, Randomized, Double Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma (vol 41, pg 795, 2021) (Journal article)
Ryoo, B. -Y., Palmer, D. H., Park, S. R., Rimassa, L., Sarker, D., Daniele, B., . . . Lim, H. Y. (2022). Efficacy and Safety Results from a Phase 2, Randomized, Double Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma (vol 41, pg 795, 2021). CLINICAL DRUG INVESTIGATION, 42(3), 283. doi:10.1007/s40261-022-01132-yDOI: 10.1007/s40261-022-01132-y
A randomised phase II clinical trial of low-dose cyclophosphamide and transarterial chemoembolization (TACE) with or without vaccination with dendritic cells (DC) pulsed with HepG2 lysate ex vivo in patients with hepatocellular carcinoma (HCC): The ImmunoTACE trial. (Conference Paper)
Ting Ma, Y., Kirkham, A., Curbishley, S., Rowe, A., Blahova, M., Mehrzad, H., . . . Adams, D. H. (2022). A randomised phase II clinical trial of low-dose cyclophosphamide and transarterial chemoembolization (TACE) with or without vaccination with dendritic cells (DC) pulsed with HepG2 lysate ex vivo in patients with hepatocellular carcinoma (HCC): The ImmunoTACE trial.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 40. Retrieved from https://www.webofscience.com/
Bellomo, G., Rainer, C., Quaranta, V., Astuti, Y., Raymant, M., Boyd, E., . . . Schmid, M. C. (n.d.). Chemotherapy-induced infiltration of neutrophils promotes pancreatic cancer metastasis via Gas6/AXL signalling axis. Gut. doi:10.1136/gutjnl-2021-325272DOI: 10.1136/gutjnl-2021-325272
Entity-independent Safety and Efficacy of Erdafitinib in Patients with advanced solid Tumors with pre-specified genomic Aberrations of <i>FGFR</i> (RAGNAR Interim Analysis) (Conference Paper)
Schuler, M., Loriot, Y., Iyer, G., Witt, O., Doi, T., Qin, S., . . . Pant, S. (2022). Entity-independent Safety and Efficacy of Erdafitinib in Patients with advanced solid Tumors with pre-specified genomic Aberrations of <i>FGFR</i> (RAGNAR Interim Analysis). In ONCOLOGY RESEARCH AND TREATMENT Vol. 45 (pp. 27-28). Retrieved from https://www.webofscience.com/
Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma (aHCC): 3-year follow-up of the phase 2 KEYNOTE-224 study. (Conference Paper)
Borbath, I., Van Laethem, J. -L., Karwal, M., Verslype, C., Van Vlierberghe, H., Kardosh, A., . . . Vogel, A. (2022). Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma (aHCC): 3-year follow-up of the phase 2 KEYNOTE-224 study.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 40. Retrieved from https://www.webofscience.com/
TARGET National: A UK-wide liquid-based molecular profiling program to enhance recruitment to early-phase trials (Conference Paper)
Ortega-Franco, A., Darlington, E., Carter, L., Cook, N., Graham, D. M., Thistlethwaite, F., . . . Krebs, M. (2022). TARGET National: A UK-wide liquid-based molecular profiling program to enhance recruitment to early-phase trials. In JOURNAL OF CLINICAL ONCOLOGY Vol. 40. Retrieved from https://www.webofscience.com/
2021
Aughton, K., Elander, N. O., Evans, A., Jackson, R., Campbell, F., Costello, E., . . . Greenhalf, W. (2021). hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. CANCERS, 13(22). doi:10.3390/cancers13225758DOI: 10.3390/cancers13225758
Childs, A., Zakeri, N., Ma, Y. T., O'Rourke, J., Ross, P., Hashem, E., . . . Meyer, T. (2021). Biopsy for advanced hepatocellular carcinoma: results of a multicentre UK audit. BRITISH JOURNAL OF CANCER, 125(10), 1350-1355. doi:10.1038/s41416-021-01535-2DOI: 10.1038/s41416-021-01535-2
Hashimoto, A., Sarker, D., Reebye, V., Jarvis, S., Sodergren, M. H., Kossenkov, A., . . . Gabrilovich, D. I. (2021). Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer. CLINICAL CANCER RESEARCH, 27(21), 5961-5978. doi:10.1158/1078-0432.CCR-21-0986DOI: 10.1158/1078-0432.CCR-21-0986
Baseline liver function and outcomes in the phase III REFLECT study in patients with unresectable hepatocellular carcinoma (uHCC) (Conference Paper)
Vogel, A., Frenette, C., Sung, M. W., Daniele, B., Baron, A. D., Chan, S. L., . . . Kudo, M. (2020). Baseline liver function and outcomes in the phase III REFLECT study in patients with unresectable hepatocellular carcinoma (uHCC). In JOURNAL OF CLINICAL ONCOLOGY Vol. 38. Retrieved from https://www.webofscience.com/
Efficacy and Safety Results from a Phase 2, Randomized, Double-Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma (Journal article)
Ryoo, B. -Y., Palmer, D. H., Park, S. R., Rimassa, L., Sarker, D., Daniele, B., . . . Lim, H. Y. (2021). Efficacy and Safety Results from a Phase 2, Randomized, Double-Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma. CLINICAL DRUG INVESTIGATION, 41(9), 795-808. doi:10.1007/s40261-021-01063-0DOI: 10.1007/s40261-021-01063-0
Mu, S., Palmer, D., Fitzgerald, R., Andreu-Vieyra, C., Zhang, H., Tang, Z., . . . Sahasranaman, S. (2021). Human Mass Balance and Metabolite Profiling of [<SUP>14</SUP>C]-Pamiparib, a Poly (ADP-Ribose) Polymerase Inhibitor, in Patients With Advanced Cancer. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 10(9), 1108-1120. doi:10.1002/cpdd.943DOI: 10.1002/cpdd.943
Edeline, J., Lamarca, A., McNamara, M. G., Jacobs, T., Hubner, R. A., Palmer, D., . . . Valle, J. W. (2021). Locoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysis. CANCER TREATMENT REVIEWS, 99. doi:10.1016/j.ctrv.2021.102258DOI: 10.1016/j.ctrv.2021.102258
Vogel, A., Frenette, C., Sung, M., Daniele, B., Baron, A., Chan, S. L., . . . Kudo, M. (2021). Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma. LIVER CANCER. doi:10.1159/000516490DOI: 10.1159/000516490
Second-line FOLFOX chemotherapy for advanced biliary tract cancer (Journal article)
Lamarca, A., Palmer, D. H., Wasan, H. S., Ross, P. J., Ma, Y. T., Arora, A., . . . Valle, J. W. (2021). Second-line FOLFOX chemotherapy for advanced biliary tract cancer. LANCET ONCOLOGY, 22(7), E288-E289. Retrieved from https://www.webofscience.com/
Loughney, L., West, M. A., Moyses, H., Bates, A., Kemp, G. J., Hawkins, L., . . . Jack, S. (2021). The effects of neoadjuvant chemoradiotherapy and an in-hospital exercise training programme on physical fitness and quality of life in locally advanced rectal cancer patients: a randomised controlled trial (The EMPOWER Trial). PERIOPERATIVE MEDICINE, 10(1). doi:10.1186/s13741-021-00190-8DOI: 10.1186/s13741-021-00190-8
Organoid Models of Cholangiocarcinoma (Chapter)
Gilbert, T., Quinn, M., Goldring, C., Palmer, D., Braconi, C., & Malik, H. (2021). Organoid Models of Cholangiocarcinoma. In Diagnosis and Management of Cholangiocarcinoma (pp. 495-508). Springer International Publishing. doi:10.1007/978-3-030-70936-5_23DOI: 10.1007/978-3-030-70936-5_23
Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase 2 KEYNOTE-224 study. (Conference Paper)
Van Laethem, J. -L., Borbath, I., Karwal, M., Verslype, C., Van Vlierberghe, H., Kardosh, A., . . . Zhu, A. X. (2021). Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase 2 KEYNOTE-224 study.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 39. doi:10.1200/JCO.2021.39.15_suppl.4074DOI: 10.1200/JCO.2021.39.15_suppl.4074
Phase III study of NUC-1031+cisplatin versus gemcitabine plus cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121). (Conference Paper)
Knox, J. J., McNamara, M. G., Goyal, L., Cosgrove, D., Springfeld, C., Sjoquist, K. M., . . . Valle, J. W. (2021). Phase III study of NUC-1031+cisplatin versus gemcitabine plus cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 39. doi:10.1200/JCO.2021.39.15_suppl.TPS4164DOI: 10.1200/JCO.2021.39.15_suppl.TPS4164
Lamarca, A., Palmer, D. H., Wasan, H. S., Ross, P. J., Ma, Y. T., Arora, A., . . . Valle, J. W. (2021). Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. LANCET ONCOLOGY, 22(5), 690-701. doi:10.1016/S1470-2045(21)00027-9DOI: 10.1016/S1470-2045(21)00027-9
A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08) (Journal article)
McNamara, M. G., Bridgewater, J., Palmer, D. H., Faluyi, O., Wasan, H., Patel, A., . . . Valle, J. W. (2021). A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08). ONCOLOGIST, 26(4), E669-E678. doi:10.1002/onco.13598DOI: 10.1002/onco.13598
Kudo, M., Galle, P. R., Brandi, G., Kang, Y. -K., Yen, C. -J., Finn, R. S., . . . Zhu, A. X. (2021). Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2. JHEP REPORTS, 3(2). doi:10.1016/j.jhepr.2020.100215DOI: 10.1016/j.jhepr.2020.100215
Lee, R. J., Wysocki, O., Bhogal, T., Shotton, R., Tivey, A., Angelakas, A., . . . Armstrong, A. C. (2021). Erratum to "Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during COVID-19 reveals features associated with outcome". ESMO OPEN, 6(2). doi:10.1016/j.esmoop.2021.100056DOI: 10.1016/j.esmoop.2021.100056
Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic" (Journal article)
Jones, C. M., Radhakrishna, G., Aitken, K., Bridgewater, J., Corrie, P., Eatock, M., . . . Mukherjee, S. (2021). Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". BRITISH JOURNAL OF CANCER, 124(3), 679-680. doi:10.1038/s41416-020-01133-8DOI: 10.1038/s41416-020-01133-8
Lee, R. J., Wysocki, O., Bhogal, T., Shotton, R., Tivey, A., Angelakas, A., . . . Armstrong, A. C. (2021). Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during COVID-19 reveals features associated with outcome. ESMO OPEN, 6(1). doi:10.1016/j.esmoop.2020.100005DOI: 10.1016/j.esmoop.2020.100005
Bhogal, T., Khan, U. T., Lee, R., Stockdale, A., Hesford, C., Potti-Dhananjaya, V., . . . Palmieri, C. (2021). Haematological malignancy and nosocomial transmission are associated with an increased risk of death from COVID-19: results of a multi-center UK cohort.. Leukemia & lymphoma, 1-16. doi:10.1080/10428194.2021.1876865DOI: 10.1080/10428194.2021.1876865
A phase III, double-blind, randomized study of nivolumab (NIVO) and ipilimumab (IPI), nivo monotherapy or placebo plus transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC). (Conference Paper)
Sangro, B., Harding, J. J., Johnson, M., Palmer, D. H., Edeline, J., Abou-Alfa, G. K., . . . Kudo, M. (2021). A phase III, double-blind, randomized study of nivolumab (NIVO) and ipilimumab (IPI), nivo monotherapy or placebo plus transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 39. doi:10.1200/JCO.2021.39.3_suppl.TPS349DOI: 10.1200/JCO.2021.39.3_suppl.TPS349
Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase II KEYNOTE-224 study. (Conference Paper)
Van Laethem, J. -L., Borbath, I., Karwal, M., Verslype, C., Van Vlierberghe, H., Kardosh, A., . . . Zhu, A. X. (2021). Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase II KEYNOTE-224 study.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 39. doi:10.1200/JCO.2021.39.3_suppl.297DOI: 10.1200/JCO.2021.39.3_suppl.297
Phase III study of NUC-1031+cisplatin vs gemcitabine plus cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121). (Conference Paper)
Knox, J. J., McNamara, M. G., Goyal, L., Cosgrove, D., Springfeld, C., Sjoquist, K. M., . . . Valle, J. W. (2021). Phase III study of NUC-1031+cisplatin vs gemcitabine plus cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 39. doi:10.1200/JCO.2021.39.3_suppl.TPS351DOI: 10.1200/JCO.2021.39.3_suppl.TPS351
Real-world study of treatment patterns and outcomes among patients with metastatic pancreatic ductal adenocarcinoma (PDAC) in Europe. (Conference Paper)
Taieb, J., Hammel, P., Reni, M., Palmer, D. H., Bridgewater, J. A., Cubillo, A., . . . Macarulla, T. (2021). Real-world study of treatment patterns and outcomes among patients with metastatic pancreatic ductal adenocarcinoma (PDAC) in Europe.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 39. doi:10.1200/JCO.2021.39.3_suppl.391DOI: 10.1200/JCO.2021.39.3_suppl.391
2020
Halloran, C., Neoptolemos, J. P., Platt, K., Jackson, R., Reddy, S., Oreily, D., . . . Ghaneh, P. (2020). PANasta Trial: Cattell Warren versus Blumgart techniques of pancreatico-jejunostomy following pancreato-duodenectomy-A double-blinded multi-centered trial, trial results.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 38. Retrieved from https://www.webofscience.com/
Jones, C. M., Radhakrishna, G., Aitken, K., Bridgewater, J., Corrie, P., Eatock, M., . . . Mukherjee, S. (2020). Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. BRITISH JOURNAL OF CANCER, 123(5), 709-713. doi:10.1038/s41416-020-0980-xDOI: 10.1038/s41416-020-0980-x
Sarker, D., Plummer, R., Meyer, T., Sodergren, M. H., Basu, B., Chee, C. E., . . . Habib, N. (2020). MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-a, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial. CLINICAL CANCER RESEARCH, 26(15), 3936-3946. doi:10.1158/1078-0432.CCR-20-0414DOI: 10.1158/1078-0432.CCR-20-0414
Han, G., Berhane, S., Toyoda, H., Bettinger, D., Elshaarawy, O., Chan, A. W. H., . . . Johnson, P. J. (2020). Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach. Hepatology (Baltimore, Md.), 72(01), 198-212. doi:10.1002/hep.31022DOI: 10.1002/hep.31022
NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials. (Journal article)
Kapacee, Z. A., Knox, J. J., Palmer, D., Blagden, S. P., Lamarca, A., Valle, J. W., & McNamara, M. G. (2020). NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials.. Medical oncology (Northwood, London, England), 37(7), 61. doi:10.1007/s12032-020-01386-6DOI: 10.1007/s12032-020-01386-6
McNamara, M. G., Goyal, L., Doherty, M., Springfeld, C., Cosgrove, D., Sjoquist, K. M., . . . Knox, J. J. (2020). NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121). FUTURE ONCOLOGY, 16(16), 1069-1081. doi:10.2217/fon-2020-0247DOI: 10.2217/fon-2020-0247
Palmieri, C., Palmer, D., Openshaw, P. J., Baille, J. K., Semple, M. G., & Turtle, L. (2020). Cancer datasets and the SARS-CoV-2 pandemic: establishing principles for collaboration.. ESMO Open, 5(3). doi:10.1136/esmoopen-2020-000825DOI: 10.1136/esmoopen-2020-000825
Palmer, D. H., Valle, J. W., Ting Ma, Y., Faluyi, O., Neoptolemos, J. P., Jensen Gjertsen, T., . . . Dueland, S. (2020). TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial. BRITISH JOURNAL OF CANCER, 122(7), 971-977. doi:10.1038/s41416-020-0752-7DOI: 10.1038/s41416-020-0752-7
Role of locoregional therapies in the wake of systemic therapy (Journal article)
Palmer, D. H., Malagari, K., & Kulik, L. M. (2020). Role of locoregional therapies in the wake of systemic therapy. JOURNAL OF HEPATOLOGY, 72(2), 277-287. doi:10.1016/j.jhep.2019.09.023DOI: 10.1016/j.jhep.2019.09.023
Elmetwali, T., Salman, A., Wei, W., Hussain, S. A., Young, L. S., & Palmer, D. H. (2020). CD40L membrane retention enhances the immunostimulatory effects of CD40 ligation. SCIENTIFIC REPORTS, 10(1). doi:10.1038/s41598-019-57293-yDOI: 10.1038/s41598-019-57293-y
ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma: Five year follow-up. (Conference Paper)
Neoptolemos, J. P., Palmer, D. H., Ghaneh, P., Valle, J. W., Cunningham, D., Wadsley, J., . . . Buchler, M. W. (2020). ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma: Five year follow-up.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 38. Retrieved from https://www.webofscience.com/
First-in-human phase I trial of small activating RNA (saRNA) oligonucleotide MTL-CEBPA in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) (Conference Paper)
Sarker, D., Sodergren, M., Plummer, E. R., Basu, B., Meyer, T., Huang, K. -W., . . . Habib, N. A. (2020). First-in-human phase I trial of small activating RNA (saRNA) oligonucleotide MTL-CEBPA in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC). In JOURNAL OF CLINICAL ONCOLOGY Vol. 38. Retrieved from https://www.webofscience.com/
NUC-1031 in combination with cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121) (Conference Paper)
Knox, J. J., McNamara, M. G., Goyal, L., Doherty, M., Springfeld, C., Park, J. O., . . . Valle, J. W. (2020). NUC-1031 in combination with cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121). In JOURNAL OF CLINICAL ONCOLOGY Vol. 38. Retrieved from https://www.webofscience.com/
Phase Ib dose escalation and cohort expansion study of the novel myeloid differentiating agent MTL-CEBPA in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC). (Conference Paper)
Sarker, D., Sodergren, M., Plummer, E. R., Basu, B., Meyer, T., Huang, K. -W., . . . Habib, N. A. (2020). Phase Ib dose escalation and cohort expansion study of the novel myeloid differentiating agent MTL-CEBPA in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 38. Retrieved from https://www.webofscience.com/
Real-world experience of regorafenib in patients with hepatocellular carcinoma: A multicenter United Kingdom study (Conference Paper)
Ross, P. J., Ma, Y. T., Palmer, D. H., Lythgoe, M. P., Merrick, S., Samson, A., . . . Thillai, K. (2020). Real-world experience of regorafenib in patients with hepatocellular carcinoma: A multicenter United Kingdom study. In JOURNAL OF CLINICAL ONCOLOGY Vol. 38. Retrieved from https://www.webofscience.com/
Updated efficacy and safety of KEYNOTE-224: A phase II study of pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC) (Conference Paper)
Kudo, M., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D. H., . . . Zhu, A. X. (2020). Updated efficacy and safety of KEYNOTE-224: A phase II study of pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC). In JOURNAL OF CLINICAL ONCOLOGY Vol. 38. Retrieved from https://www.webofscience.com/
2019
Evans, J. P., Winiarski, B. K., Sutton, P. A., Ressel, L., Duckworth, C. A., Pritchard, D. M., . . . Kitteringham, N. R. (2019). Development of an orthotopic syngeneic murine model of colorectal cancer for use in translational research. LABORATORY ANIMALS, 53(6), 598-609. doi:10.1177/0023677219826165DOI: 10.1177/0023677219826165
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma (Journal article)
Kim, R. D., Sarker, D., Meyer, T., Yau, T., Macarulla, T., Park, J. -W., . . . Kang, Y. -K. (2019). First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma. CANCER DISCOVERY, 9(12), 1696-1707. doi:10.1158/2159-8290.CD-19-0555DOI: 10.1158/2159-8290.CD-19-0555
Jones, R. P., Psarelli, E. -E., Jackson, R., Ghaneh, P., Halloran, C. M., Palmer, D. H., . . . Millat, B. (2019). Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial. JAMA SURGERY, 154(11), 1038-1048. doi:10.1001/jamasurg.2019.3337DOI: 10.1001/jamasurg.2019.3337
Evaluation of the utility of prognostic models for patients with resected hilar cholangiocarcinoma (Journal article)
Bird, N. T. E., Manu, N., Quinn, L., Needham, A., Jones, R., Fenwick, S., . . . Malik, H. (2019). Evaluation of the utility of prognostic models for patients with resected hilar cholangiocarcinoma. HPB, 21(10), 1376-1384. doi:10.1016/j.hpb.2019.02.014DOI: 10.1016/j.hpb.2019.02.014
Johnson, P. (2019). The Epidemiology of Hepatocellular Carcinoma. In Liver Cancers (pp. 3-11). Springer International Publishing. doi:10.1007/978-3-319-92216-4_1DOI: 10.1007/978-3-319-92216-4_1
Increased multimodality treatment options has improved survival for Hepatocellular carcinoma but poor survival for biliary tract cancers remains unchanged (Journal article)
Alabraba, E., Joshi, H., Bird, N., Griffin, R., Sturgess, R., Stern, N., . . . Malik, H. (2019). Increased multimodality treatment options has improved survival for Hepatocellular carcinoma but poor survival for biliary tract cancers remains unchanged. EJSO, 45(9), 1660-1667. doi:10.1016/j.ejso.2019.04.002DOI: 10.1016/j.ejso.2019.04.002
ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC plus mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy. (Conference Paper)
Lamarca, A., Palmer, D. H., Wasan, H. S., Ross, P. J., Ma, Y. T., Arora, A., . . . Valle, J. W. (2019). ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC plus mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 37. doi:10.1200/JCO.2019.37.15_suppl.4003DOI: 10.1200/JCO.2019.37.15_suppl.4003
NUC-1031 in combination with cisplatin for first-line treatment of advanced biliary tract cancer. (Conference Paper)
Knox, J. J., McNamara, M. G., Palmer, D. H., Evans, T. R. J., Goldstein, D., Bridgewater, J. A., & Valle, J. W. (2019). NUC-1031 in combination with cisplatin for first-line treatment of advanced biliary tract cancer.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 37. doi:10.1200/JCO.2019.37.15_suppl.TPS4156DOI: 10.1200/JCO.2019.37.15_suppl.TPS4156
Primrose, J. N., Fox, R. P., Palmer, D. H., Malik, H. Z., Prasad, R., Mirza, D., . . . Grp, B. I. L. C. A. P. S. (2019). Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. LANCET ONCOLOGY, 20(5), 663-673. doi:10.1016/S1470-2045(18)30915-XDOI: 10.1016/S1470-2045(18)30915-X
Chemotherapy for pancreatic cancer (Journal article)
Springfeld, C., Jaeger, D., Buechler, M. W., Strobel, O., Hackert, T., Palmer, D. H., & Neoptolemos, J. P. (2019). Chemotherapy for pancreatic cancer. PRESSE MEDICALE, 48(3), E159-E174. doi:10.1016/j.lpm.2019.02.025DOI: 10.1016/j.lpm.2019.02.025
The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma (Journal article)
Ghaneh, P., Kleeff, J., Halloran, C. M., Raraty, M., Jackson, R., Melling, J., . . . Smith, C. (2019). The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma. Annals of Surgery, 269(03), 520-529. doi:10.1097/SLA.0000000000002557DOI: 10.1097/SLA.0000000000002557
Evans, J. P., Winiarski, B. K., Sutton, P. A., Jones, R. P., Ressel, L., Duckworth, C. A., . . . Kitteringham, N. R. (2019). Correction: The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer.. Oncotarget, 10(6), 685. doi:10.18632/oncotarget.26625DOI: 10.18632/oncotarget.26625
ABC-06 | A randomised phase III study of Active Symptom Control (ASC) with/without mFOLFOX after progression to Cisplatin-Gemcitabine chemotherapy for patients with advanced biliary tract cancers (Conference Paper)
Lamarca, A., Palmer, D. H., Wasan, H. S., Ross, P. J., Ma, Y. T., Arora, A., . . . Valle, J. W. (2019). ABC-06 | A randomised phase III study of Active Symptom Control (ASC) with/without mFOLFOX after progression to Cisplatin-Gemcitabine chemotherapy for patients with advanced biliary tract cancers. In BRITISH JOURNAL OF CANCER Vol. 121 (pp. 19). Retrieved from https://www.webofscience.com/
First-in-human, first-in-class phase I study of MTL-CEBPA, a RNA oligonucleotide targeting the myeloid cell master regulator C/EBP-α, in patients with advanced hepatocellular cancer (HCC) (Conference Paper)
Sarker, D., Plummer, R., Basu, B., Meyer, T., Ma, Y. -T., Evans, J., . . . Habib, N. (2019). First-in-human, first-in-class phase I study of MTL-CEBPA, a RNA oligonucleotide targeting the myeloid cell master regulator C/EBP-α, in patients with advanced hepatocellular cancer (HCC). In ANNALS OF ONCOLOGY Vol. 30 (pp. 168-+). Retrieved from https://www.webofscience.com/
Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe. (Journal article)
Javed, M. A., Beyer, G., Le, N., Vinci, A., Wong, H., Palmer, D., . . . Krug, S. (2019). Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe.. Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 19(1), 97-104. doi:10.1016/j.pan.2018.10.003DOI: 10.1016/j.pan.2018.10.003
Overall survival of patients with hepatocellular carcinoma receiving sorafenib versus selective internal radiation therapy with predicted osimetry in the SARAH trial (Conference Paper)
Hawkins, N. S., Ross, P. J., Palmer, D. H., Chatellier, G., Pereira, H., & Vilgrain, V. (2019). Overall survival of patients with hepatocellular carcinoma receiving sorafenib versus selective internal radiation therapy with predicted osimetry in the SARAH trial. In ANNALS OF ONCOLOGY Vol. 30. Retrieved from https://www.webofscience.com/
Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma (PDAC) in the ESPAC-4 Randomized Adjuvant Chemotherapy Trial (Conference Paper)
Neoptolemos, J. P., Jones, R. P., Psarelli, E. E., Jackson, R., Ghaneh, P., Halloran, C. M., . . . Buechler, M. W. (2019). Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma (PDAC) in the ESPAC-4 Randomized Adjuvant Chemotherapy Trial. In PANCREAS Vol. 48 (pp. 1497-1498). Retrieved from https://www.webofscience.com/
Selection of patients with hepatocellular carcinoma for selective internal radiation therapy based on tumour burden and liver function: A post-hoc analysis of the SARAH trial (Conference Paper)
Palmer, D. H., Hawkins, N. S., Vilgrain, V., Pereira, H., Chatellier, G., & Ross, P. J. (2019). Selection of patients with hepatocellular carcinoma for selective internal radiation therapy based on tumour burden and liver function: A post-hoc analysis of the SARAH trial. In ANNALS OF ONCOLOGY Vol. 30 (pp. 282). Retrieved from https://www.webofscience.com/
Tumor burden and liver function in HCC patient selection for selective internal radiation therapy: SARAH post-hoc study (Journal article)
Palmer, D. H., Hawkins, N. S., Vilgrain, V., Pereira, H., Chatellier, G., & Ross, P. J. (2020). Tumor burden and liver function in HCC patient selection for selective internal radiation therapy: SARAH post-hoc study. FUTURE ONCOLOGY, 16(1), 4315-4325. doi:10.2217/fon-2019-0658DOI: 10.2217/fon-2019-0658
hENT1 RNA and Protein in Combination May Act as Predictive Biomarkers for Survival for Patients Treated With Adjuvant Gemcitabine in Pancreatic Cancer (Conference Paper)
Hale, J., Evans, A., Aughton, K., Elander, N. O., Ghaneh, P., Neoptolemos, J. P., . . . Greenhalf, W. (2019). hENT1 RNA and Protein in Combination May Act as Predictive Biomarkers for Survival for Patients Treated With Adjuvant Gemcitabine in Pancreatic Cancer. In PANCREAS Vol. 48 (pp. 1436-1437). Retrieved from https://www.webofscience.com/
2018
Mahajan, U. M., Langhoff, E., Goni, E., Costello, E., Greenhalf, W., Halloran, C. M., . . . Mayerle, J. (2018). Immune Cell and Stromal Signature Associated with Progression-free Survival of Patients with Resected Pancreatic Ductal Adenocarcinoma. Gastroenterology, 155(05), 1625-1639.E2. doi:10.1053/j.gastro.2018.08.009DOI: 10.1053/j.gastro.2018.08.009
ACELARATE: A randomised phase III, open label, clinical study comparing NUC-1031 with gemcitabine in patients with metastatic pancreatic carcinoma (Conference Paper)
Palmer, D. H., Ross, P. J., Silcocks, P., Greenhalf, W., Faluyi, O., Ma, Y. T., . . . Bridgewater, J. (2018). ACELARATE: A randomised phase III, open label, clinical study comparing NUC-1031 with gemcitabine in patients with metastatic pancreatic carcinoma. In ANNALS OF ONCOLOGY Vol. 29. Retrieved from https://www.webofscience.com/
Stainthorpe, A., Greenhalgh, J., Bagust, A., Richardson, M., Boland, A., Beale, S., . . . Palmer, D. (2018). Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 36(10), 1153-1163. doi:10.1007/s40273-018-0646-1DOI: 10.1007/s40273-018-0646-1
Quaranta, V., Rainer, C., Nielsen, S., Raymant, M., Ahmed, M., Engle, D., . . . Schmid, M. C. (2018). Macrophage-derived granulin drives resistance to immune checkpoint inhibition in metastatic pancreatic cancer. Cancer Research, 78(15), 4253-4269. doi:10.1158/0008-5472.CAN-17-3876DOI: 10.1158/0008-5472.CAN-17-3876
Backen, A. C., Lopes, A., Wasan, H., Palmer, D. H., Duggan, M., Cunningham, D., . . . Valle, J. W. (2018). Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial. British Journal of Cancer, 119(1), 27-35. doi:10.1038/s41416-018-0132-8DOI: 10.1038/s41416-018-0132-8
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial (Journal article)
Zhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., . . . Kudo, M. (2018). Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. LANCET ONCOLOGY, 19(7), 940-952. doi:10.1016/S1470-2045(18)30351-6DOI: 10.1016/S1470-2045(18)30351-6
Evans, J. P., Winiarski, B. K., Sutton, P. A., Jones, R. P., Ressel, L., Duckworth, C. A., . . . Kitteringham, N. R. (2018). The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer. Oncotarget, 9(43), 27104-27116. doi:10.18632/oncotarget.25497DOI: 10.18632/oncotarget.25497
Neoptolemos, J. P., Kleeff, J., Michl, P., Costello, E., Greenhalf, W., & Palmer, D. H. (2018). Therapeutic developments in pancreatic cancer: current and future perspectives. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 15(6), 333-348. doi:10.1038/s41575-018-0005-xDOI: 10.1038/s41575-018-0005-x
Pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC): KEYNOTE-224 update. (Conference Paper)
Zhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D. H., . . . Kudo, M. (2018). Pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC): KEYNOTE-224 update.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36. doi:10.1200/JCO.2018.36.15_suppl.4020DOI: 10.1200/JCO.2018.36.15_suppl.4020
Preliminary results of a first-in-human, first-in-class phase I study of MTL-CEBPA, a small activating RNA (saRNA) targeting the transcription factor C/EBP-α in patients with advanced liver cancer. (Conference Paper)
Sarker, D., Plummer, E. R., Basu, B., Meyer, T., Huang, K. -W., Evans, T. R. J., . . . Habib, N. A. (2018). Preliminary results of a first-in-human, first-in-class phase I study of MTL-CEBPA, a small activating RNA (saRNA) targeting the transcription factor C/EBP-α in patients with advanced liver cancer.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36. doi:10.1200/JCO.2018.36.15_suppl.2509DOI: 10.1200/JCO.2018.36.15_suppl.2509
Bowden, D. L., Sutton, P. A., Wall, M. A., Jithesh, P. V., Jenkins, R. E., Palmer, D. H., . . . Vimalachandran, D. (2018). Proteomic profiling of rectal cancer reveals acid ceramidase is implicated in radiation response. JOURNAL OF PROTEOMICS, 179, 53-60. doi:10.1016/j.jprot.2018.02.030DOI: 10.1016/j.jprot.2018.02.030
Palmer, D. H., Ma, Y. T., Peck-Radosavljevic, M., Ross, P., Graham, J., Fartoux, L., . . . Meyer, T. (2018). A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma. British Journal of Cancer, 118, 1162-1168. doi:10.1038/s41416-018-0051-8DOI: 10.1038/s41416-018-0051-8
Elander, N. O., Aughton, K., Ghaneh, P., Neoptolemos, J. P., Palmer, D. H., Cox, T. F., . . . Canc, E. S. G. P. (2018). Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy. British Journal of Cancer, 118, 1084-1088. doi:10.1038/s41416-018-0005-1DOI: 10.1038/s41416-018-0005-1
Elander, N. O., Aughton, K., Ghaneh, P., Neoptolemos, J. P., Palmer, D. H., Cox, T. F., . . . Greenhalf, W. (2018). Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predict survival in pancreatic cancer.. British Journal of Cancer, 118(7), 947-954. doi:10.1038/s41416-018-0004-2DOI: 10.1038/s41416-018-0004-2
Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal (Journal article)
Fleeman, N., Abdulla, A., Bagust, A., Beale, S., Richardson, M., Stainthorpe, A., . . . Palmer, D. (2018). Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS, 36(3), 289-299. doi:10.1007/s40273-017-0592-3DOI: 10.1007/s40273-017-0592-3
ABC-08: A phase Ib, multi-centre, open-label study of a first-in-class nucleotide analogue NUC-1031 in combination with cisplatin in patients with locally advanced/metastatic biliary tract cancers. (Conference Paper)
McNamara, M. G., Bridgewater, J. A., Palmer, D. H., Wasan, H. S., Ryder, D., Gnanaranjan, C., . . . Valle, J. W. (2018). ABC-08: A phase Ib, multi-centre, open-label study of a first-in-class nucleotide analogue NUC-1031 in combination with cisplatin in patients with locally advanced/metastatic biliary tract cancers.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36. doi:10.1200/JCO.2018.36.4_suppl.TPS544DOI: 10.1200/JCO.2018.36.4_suppl.TPS544
Palmer, D. H., Ross, P. J., Silcocks, P., Greenhalf, W., Faluyi, O. O., Ma, Y. T., . . . Neoptolemos, J. P. (2018). ACELARATE: A phase III, open label, multicentre randomised clinical study comparing Acelarin (NUC-1031) with gemcitabine in patients with metastatic pancreatic carcinoma.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36. doi:10.1200/JCO.2018.36.4_suppl.TPS537DOI: 10.1200/JCO.2018.36.4_suppl.TPS537
Halloran, C. M. (2018). Cytoplasmic HuR Status Predicts Disease-Free Survival in Resected Pancreatic Cancer: A Post-Hoc Analysis from the International Multi-Institutional Phase III ESPAC-3 Clinical Trial. Annals of Surgery, 267(2), 364-369. doi:10.1097/SLA.0000000000002088DOI: 10.1097/SLA.0000000000002088
KEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. (Conference Paper)
Zhu, A. X., Finn, R. S., Cattan, S., Edeline, J., Ogasawara, S., Palmer, D. H., . . . Kudo, M. (2018). KEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36. doi:10.1200/JCO.2018.36.4_suppl.209DOI: 10.1200/JCO.2018.36.4_suppl.209
Sutton, P. A., Jithesh, P. V., Jones, R. P., Evans, J. P., Vimalachandran, D., Malik, H. Z., . . . Kitteringham, N. R. (2018). Exome sequencing of synchronously resected primary colorectal tumours and colorectal liver metastases to inform oncosurgical management. EJSO - European Journal of Surgical Oncology, 44(1), 115-121. doi:10.1016/j.ejso.2017.10.211DOI: 10.1016/j.ejso.2017.10.211
PhotoChemical internalization of gemcitabine followed by gemcitabine/cisplatin in perihilar cholangiocarcinoma: Results from a phase I dose escalation trial (Conference Paper)
Trojan, J., Sturgess, R., Palmer, D. H., Neu, B., Kasper, S., Dechene, A., . . . Olivecrona, H. (2018). PhotoChemical internalization of gemcitabine followed by gemcitabine/cisplatin in perihilar cholangiocarcinoma: Results from a phase I dose escalation trial. In ANNALS OF ONCOLOGY Vol. 29. Retrieved from https://www.webofscience.com/
2017
Edeline, J., Blanc, J. -F., Campillo-Gimenez, B., Ma, Y. -T., King, J., Faluyi, O., . . . Meyer, T. (2017). Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score. European Journal of Cancer, 86, 135-142. doi:10.1016/j.ejca.2017.08.036DOI: 10.1016/j.ejca.2017.08.036
Ma, Y. T., Leonard, S. M., Gordon, N., Anderton, J., James, C., Huen, D., . . . Palmer, D. H. (2017). Use of a genome-wide haploid genetic screen to identify treatment predicting factors: a proof-of-principle study in pancreatic cancer.. Oncotarget, 8(38), 63635-63645. doi:10.18632/oncotarget.18879DOI: 10.18632/oncotarget.18879
Meyer, T., Fox, R., Ma, Y. T., Ross, P. J., James, M. W., Sturgess, R., . . . Palmer, D. H. (2017). Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2(8), 565-575. doi:10.1016/S2468-1253(17)30156-5DOI: 10.1016/S2468-1253(17)30156-5
Meyer, T., Palmer, D. H., Cheng, A. -L., Hocke, J., Loembe, A. -B., & Yen, C. -J. (2017). mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib. LIVER INTERNATIONAL, 37(07), 1047-1055. doi:10.1111/liv.13359DOI: 10.1111/liv.13359
Ma, Y. T., Leonard, S. M., Gordon, N., Anderton, J., James, C., Huen, D., . . . Palmer, D. H. (2017). Use of a genome-wide haploid genetic screen to identify treatment predicting factors: a proof-of-principle study in pancreatic cancer. ONCOTARGET, 8(38), 63635-63645. doi:10.18632/oncotarget.18879DOI: 10.18632/oncotarget.18879
Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine: A Pan-European study. (Conference Paper)
Javed, M. A., Beyer, G., Le, N. N. H., Vinci, A., Wong, H., Palmer, D. H., . . . Krug, S. (2017). Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine: A Pan-European study.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 35. doi:10.1200/JCO.2017.35.15_suppl.e15774DOI: 10.1200/JCO.2017.35.15_suppl.e15774
Psarelli, E. E., Jackson, R., Neoptolemos, J. P., Palmer, D. H., Ghaneh, P., Halloran, C. M., & Buechler, M. W. (2017). Beyond ESPAC-4: better surgery and systemic therapy. LANCET, 389(10078), 1517-1518. doi:10.1016/S0140-6736(17)30947-9DOI: 10.1016/S0140-6736(17)30947-9
Totti, S., Vernardis, S. I., Meira, L., Perez-Mancere, P. A., Costello, E., Greenhalf, W., . . . Velliou, E. G. (2017). Designing a bio-inspired biomimetic <i>in vitro</i> system for the optimization of <i>ex vivo</i> studies of pancreatic cancer. DRUG DISCOVERY TODAY, 22(4), 690-701. Retrieved from https://www.webofscience.com/
Hussain, S., Palmer, D., Syn, W. K., Sacco, J., Greensmith, R. M. D., Elmetwali, T., . . . Collins, S. (2017). Gene expression profiling in bladder cancer identifies potential therapeutic targets. International Journal of Oncology, 50(4), 1147-1159. doi:10.3892/ijo.2017.3893DOI: 10.3892/ijo.2017.3893
Hussain, S. A., Palmer, D. H., Syn, W. K., Sacco, J. J., Lloyd, B., Jithesh, P., . . . James, N. D. (2013). Gene expression profiling in bladder cancer to identify potential therapeutic targets. JOURNAL OF CLINICAL ONCOLOGY, 31(15). Retrieved from https://www.webofscience.com/
King, J., Palmer, D. H., Johnson, P., Ross, P., Hubner, R. A., Sumpter, K., . . . Meyer, T. (2017). Sorafenib for the Treatment of Advanced Hepatocellular Cancer - a UK Audit.. Clinical oncology (Royal College of Radiologists (Great Britain)), 29(4), 256-262. doi:10.1016/j.clon.2016.11.012DOI: 10.1016/j.clon.2016.11.012
Middleton, G., Palmer, D. H., Greenhalf, W., Ghaneh, P., Jackson, R., Cox, T., . . . Neoptolemos, J. P. (2017). Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial. The Lancet Oncology, 18(4), 486-499. doi:10.1016/S1470-2045(17)30084-0DOI: 10.1016/S1470-2045(17)30084-0
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. (Journal article)
Neoptolemos, J. P., Palmer, D. H., Ghaneh, P., Psarelli, E. E., Valle, J. W., Halloran, C. M., . . . Büchler, M. W. (2017). Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.. Lancet (London, England), 389(10073), 1011-1024. doi:10.1016/s0140-6736(16)32409-6DOI: 10.1016/s0140-6736(16)32409-6
Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy (Journal article)
Bird, N. T. E., Elmasry, M., Jones, R., Psarelli, E., Dodd, J., Malik, H., . . . Palmer, D. (2017). Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy. BRITISH JOURNAL OF SURGERY, 104(4), 328-336. doi:10.1002/bjs.10482DOI: 10.1002/bjs.10482
Role of staging laparoscopy in the stratification of patients with perihilar cholangiocarcinoma (Journal article)
Bird, N., Elmasry, M., Jones, R., Elniel, M., Kelly, M., Palmer, D., . . . Malik, H. (2017). Role of staging laparoscopy in the stratification of patients with perihilar cholangiocarcinoma. BRITISH JOURNAL OF SURGERY, 104(4), 418-425. doi:10.1002/bjs.10399DOI: 10.1002/bjs.10399
Faluyi, O. O., Connor, J. L., Chatterjee, M., Ikin, C., Wong, H., & Palmer, D. H. (2017). Advanced pancreatic adenocarcinoma outcomes with transition from devolved to centralised care in a regional Cancer Centre. BRITISH JOURNAL OF CANCER, 116(04), 424-431. doi:10.1038/bjc.2016.406DOI: 10.1038/bjc.2016.406
Waked, I., Berhane, S., Toyoda, H., Chan, S. L., Stern, N., Palmer, D., . . . Johnson, P. J. (2017). Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion. BRITISH JOURNAL OF CANCER, 116(4), 448-454. doi:10.1038/bjc.2016.423DOI: 10.1038/bjc.2016.423
A randomized phase II trial comparing different schedules of nab-paclitaxel (nabP) combined with gemcitabine (GEM) as first line treatment for metastatic pancreatic adenocarcinoma (PDAC). (Conference Paper)
Corrie, P., Qian, W., Basu, B., Jodrell, D. I., Falk, S., Iwuji, C., . . . Valle, J. W. (2017). A randomized phase II trial comparing different schedules of nab-paclitaxel (nabP) combined with gemcitabine (GEM) as first line treatment for metastatic pancreatic adenocarcinoma (PDAC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 35. doi:10.1200/JCO.2017.35.4_suppl.342DOI: 10.1200/JCO.2017.35.4_suppl.342
2016
Edeline, J., Blanc, J. -F., Johnson, P., Campillo-Gimenez, B., Ross, P., Ma, Y. T., . . . Meyer, T. (2016). A multicentre comparison between Child Pugh and Albumin‐Bilirubin scores in patients treated with sorafenib for Hepatocellular Carcinoma. Liver international : official journal of the International Association for the Study of the Liver, 36(12), 1821-1828. doi:10.1111/liv.13170DOI: 10.1111/liv.13170
Connor, A. A., Denroche, R. E., Jang, G. H., Timms, L., Kalimuthu, S. N., Selander, I., . . . Gallinger, S. (2016). Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma.. JAMA oncology, 3(6), 774-783. doi:10.1001/jamaoncol.2016.3916DOI: 10.1001/jamaoncol.2016.3916
Intensified chemotherapy for metastatic pancreatic cancer: interim analysis of a large retrospective pan-European database and real life evaluation (Conference Paper)
Krug, S., Beyer, G., Javed, M. A., Le, N., Vinci, A., Morgan, R. D., . . . Schober, M. (2016). Intensified chemotherapy for metastatic pancreatic cancer: interim analysis of a large retrospective pan-European database and real life evaluation. In ANNALS OF ONCOLOGY Vol. 27. doi:10.1093/annonc/mdw371.68DOI: 10.1093/annonc/mdw371.68
Kleeff, J., Costello, E., Jackson, R., Halloran, C., Greenhalf, W., Ghaneh, P., . . . Neoptolemos, J. P. (2016). The impact of diabetes mellitus on survival following resection and adjuvant chemotherapy for pancreatic cancer. BRITISH JOURNAL OF CANCER, 115(7), 887-894. doi:10.1038/bjc.2016.277DOI: 10.1038/bjc.2016.277
Nielsen, S. R., Quaranta, V., Linford, A., Emeagi, P., Rainer, C., Santos, A., . . . Schmid, M. C. (2016). Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis (vol 18, pg 549, 2016). NATURE CELL BIOLOGY, 18(7), 822. doi:10.1038/ncb3377DOI: 10.1038/ncb3377
TACE 2: A randomized placebo-controlled, double blinded, phase III trial evaluating sorafenib in combination with transarterial chemoembolisation (TACE) in patients with unresectable hepatocellular carcinoma (HCC) Background (Conference Paper)
Meyer, T., Fox, R., Ma, Y. T., Ross, P. J., James, M., Strugess, R., . . . Palmer, D. H. (2016). TACE 2: A randomized placebo-controlled, double blinded, phase III trial evaluating sorafenib in combination with transarterial chemoembolisation (TACE) in patients with unresectable hepatocellular carcinoma (HCC) Background. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34. doi:10.1200/JCO.2016.34.15_suppl.4018DOI: 10.1200/JCO.2016.34.15_suppl.4018
mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomized phase II trials comparing nintedanib versus sorafenib (Conference Paper)
Meyer, T., Palmer, D. H., Cheng, A. -L., Hocke, J., Loembe, A. -B., & Yen, C. -J. (2016). mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomized phase II trials comparing nintedanib versus sorafenib. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34. doi:10.1200/JCO.2016.34.15_suppl.4086DOI: 10.1200/JCO.2016.34.15_suppl.4086
Schmid, M. C., Nielsen, S. R., Quaranta, V., Rainer, C., Mielgo, A., Emeagi, P., . . . Engle, D. (2016). Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis. Nature Cell Biology, 18(5), 549-560. doi:10.1038/ncb3340DOI: 10.1038/ncb3340
Quality of life, long-term survivors and long-term outcome from the ABC-02 study (Journal article)
Bridgewater, J., Lopes, A., Palmer, D., Cunningham, D., Anthoney, A., Maraveyas, A., . . . Wasan, H. (2016). Quality of life, long-term survivors and long-term outcome from the ABC-02 study. BRITISH JOURNAL OF CANCER, 114(9), 965-971. doi:10.1038/bjc.2016.64DOI: 10.1038/bjc.2016.64
NORE1A induction by membrane-bound CD40L (mCD40L) contributes to CD40L-induced cell death and G1 growth arrest in p21-mediated mechanism (Journal article)
Elmetwali, T., Salman, A., & Palmer, D. H. (2016). NORE1A induction by membrane-bound CD40L (mCD40L) contributes to CD40L-induced cell death and G1 growth arrest in p21-mediated mechanism. CELL DEATH & DISEASE, 7. doi:10.1038/cddis.2016.52DOI: 10.1038/cddis.2016.52
Randomized clinical trial of prehabilitation before planned liver resection (Journal article)
Dunne, D. F. J., Jack, S., Jones, R. P., Jones, L., Lythgoe, D. T., Malik, H. Z., . . . Fenwick, S. W. (2016). Randomized clinical trial of prehabilitation before planned liver resection. BRITISH JOURNAL OF SURGERY, 103(5), 504-512. doi:10.1002/bjs.10096DOI: 10.1002/bjs.10096
Middleton, G., Greenhalf, W., Costello, E., Shaw, V., Cox, T., Ghaneh, P., . . . Neoptolemos, J. P. (2016). Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma. British Journal of Cancer, 114, 510-518. doi:10.1038/bjc.2015.468DOI: 10.1038/bjc.2015.468
A phase Ib dose escalation, safety, and tolerability study of sonidegib in combination with gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma. (Conference Paper)
Macarulla, T., Tabernero, J., Palmer, D. H., Sharma, S., Yu, K. H., Sellami, D. B., . . . Kwak, E. L. (2016). A phase Ib dose escalation, safety, and tolerability study of sonidegib in combination with gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34. doi:10.1200/jco.2016.34.4_suppl.371DOI: 10.1200/jco.2016.34.4_suppl.371
From mice to men: Murine models of colorectal cancer for use in translational research (Journal article)
Evans, J. P., Sutton, P. A., Winiarski, B. K., Fenwick, S. W., Malik, H. Z., Vimalachandran, D., . . . Kitteringham, N. R. (2016). From mice to men: Murine models of colorectal cancer for use in translational research. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 98, 94-105. doi:10.1016/j.critrevonc.2015.10.009DOI: 10.1016/j.critrevonc.2015.10.009
The effects of neoadjuvant chemoradiotherapy and an in-hospital exercise training programme on physical fitness and quality of life in locally advanced rectal cancer patients (The EMPOWER Trial): study protocol for a randomised controlled trial (Journal article)
Loughney, L., West, M. A., Kemp, G. J., Rossiter, H. B., Burke, S. M., Cox, T., . . . Jack, S. (2016). The effects of neoadjuvant chemoradiotherapy and an in-hospital exercise training programme on physical fitness and quality of life in locally advanced rectal cancer patients (The EMPOWER Trial): study protocol for a randomised controlled trial. TRIALS, 17. doi:10.1186/s13063-015-1149-4DOI: 10.1186/s13063-015-1149-4
Effect of Valvular Surgery in Carcinoid Heart Disease: An Observational Cohort Study (Journal article)
Edwards, N. C., Yuan, M., Nolan, O., Pawade, T. A., Oelofse, T., Singh, H., . . . Steeds, R. P. (2016). Effect of Valvular Surgery in Carcinoid Heart Disease: An Observational Cohort Study. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 101(1), 182-189. doi:10.1210/jc.2015-3295DOI: 10.1210/jc.2015-3295
Gene expression profiling study in bladder cancer; (Journal article)
Hussain, S. A., Palmer, D. H., Sacco, J., Lloyd, B., Puthen, J., Collins, S. I., . . . James, N. D. (2016). Gene expression profiling study in bladder cancer;. British Journal of Cancer.
Hepatocellular carcinoma (Chapter)
Jones, R. P., Palmer, D. H., & Malik, H. Z. (2016). Hepatocellular carcinoma. In Surgical Oncology: Theory and Multidisciplinary Practice, Second Edition (pp. 429-440).
2015
Evaluating the role of treatment-related toxicities in the challenges facing targeted therapies for advanced hepatocellular carcinoma (Journal article)
Palmer, D. H., & Johnson, P. J. (2015). Evaluating the role of treatment-related toxicities in the challenges facing targeted therapies for advanced hepatocellular carcinoma. CANCER AND METASTASIS REVIEWS, 34(3), 497-509. doi:10.1007/s10555-015-9580-2DOI: 10.1007/s10555-015-9580-2
Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial (Journal article)
Valle, J. W., Wasan, H., Lopes, A., Backen, A. C., Palmer, D. H., Morris, K., . . . Bridgewater, J. A. (2015). Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. The Lancet Oncology, 16(8), 967-978. doi:10.1016/S1470-2045(15)00139-4DOI: 10.1016/S1470-2045(15)00139-4
Prognostic molecular markers in resected extrahepatic biliary tract cancers; a systematic review and meta-analysis of immunohistochemically detected biomarkers (Journal article)
Jones, R. P., Bird, N. T. E., Smith, R. A., Palmer, D. H., Fenwick, S. W., Poston, G. J., & Malik, H. Z. (2015). Prognostic molecular markers in resected extrahepatic biliary tract cancers; a systematic review and meta-analysis of immunohistochemically detected biomarkers. BIOMARKERS IN MEDICINE, 9(8), 763-775. doi:10.2217/BMM.15.48DOI: 10.2217/BMM.15.48
MODULATION OF NRF2 ALTERS THE RESPONSIVENESS OF COLORECTAL CANCER CELLS TO IRINOTECAN (Conference Paper)
Evans, J. P., Winiarski, B. K., Sutton, P. A., Palmer, D. H., & Kitteringham, N. (2015). MODULATION OF NRF2 ALTERS THE RESPONSIVENESS OF COLORECTAL CANCER CELLS TO IRINOTECAN. In GUT Vol. 64 (pp. A531). doi:10.1136/gutjnl-2015-309861.1160DOI: 10.1136/gutjnl-2015-309861.1160
A prospective, single-arm, phase I/II trial of RAS peptide vaccine TG01/GM-CSF and gemcitabine as adjuvant therapy for patients with resected pancreatic adenocarcinoma (Conference Paper)
Palmer, D. H., Dueland, S., Valle, J. W., Otterhaug, T., Eriksen, J. A., Muller, H., . . . Miller, R. M. (2015). A prospective, single-arm, phase I/II trial of RAS peptide vaccine TG01/GM-CSF and gemcitabine as adjuvant therapy for patients with resected pancreatic adenocarcinoma. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33. doi:10.1200/jco.2015.33.15_suppl.4121DOI: 10.1200/jco.2015.33.15_suppl.4121
Changes in plasma biomarkers over time in patients (pts) with advanced biliary tract cancer (ABC) treated in the UK ABC-03 randomized phase II trial (Conference Paper)
Backen, A. C., McNamara, M. G., Lopes, A., Wasan, H., Palmer, D. H., Duggan, M., . . . Valle, J. W. (2015). Changes in plasma biomarkers over time in patients (pts) with advanced biliary tract cancer (ABC) treated in the UK ABC-03 randomized phase II trial. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33. doi:10.1200/jco.2015.33.15_suppl.4085DOI: 10.1200/jco.2015.33.15_suppl.4085
Efficacy and safety of nintedanib (N) versus sorafenib (S) in Caucasian and Asian patients with advanced hepatocellular carcinoma (HCC): Pooled analysis of two randomized phase II trials. (Conference Paper)
Meyer, T., Palmer, D. H., Chao, Y., Choi, C., Deptala, A., Fartoux, L., . . . Cheng, A. -L. (2015). Efficacy and safety of nintedanib (N) versus sorafenib (S) in Caucasian and Asian patients with advanced hepatocellular carcinoma (HCC): Pooled analysis of two randomized phase II trials.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33. doi:10.1200/jco.2015.33.15_suppl.4074DOI: 10.1200/jco.2015.33.15_suppl.4074
Predicting response to treatment for colorectal cancer: a review of relevant mechanisms and potential biomarkers (Journal article)
Sutton, P. A., Jones, R. P., Evans, J. P., Kitteringham, N., Goldring, C., Palmer, D. H., . . . Malik, H. Z. (2015). Predicting response to treatment for colorectal cancer: a review of relevant mechanisms and potential biomarkers. COLORECTAL CANCER, 4(2), 85-95. doi:10.2217/CRC.15.11DOI: 10.2217/CRC.15.11
Evidence of adjuvant chemotherapy of ductal pancreatic cancer (Chapter)
Sultana, A., Halloran, C., Palmer, D., Ghaneh, P., Cox, T., & Neoptolemos, J. P. (2015). Evidence of adjuvant chemotherapy of ductal pancreatic cancer. In PANCREATIC CANCER, CYSTIC NEOPLASMS, AND ENDOCRINE TUMORS: DIAGNOSIS AND MANAGEMENT (pp. 94-102). Retrieved from https://www.webofscience.com/
Proteomic analysis to identify biomarkers in the primary tumour that predict response to neoadjuvant chemotherapy in liver metastases (Journal article)
Sutton, P., Evans, J., Jones, R., Malik, H., Vimalachandran, D., Palmer, D., . . . Kitteringham, N. (2015). Proteomic analysis to identify biomarkers in the primary tumour that predict response to neoadjuvant chemotherapy in liver metastases. LANCET, 385, 95. Retrieved from https://www.webofscience.com/
Assessment of liver function in patients with hepatocellular caicnoma: a new evidence-based approach - The ALBI Grade (Journal article)
Johnson, P., & Berhane, S. (2015). Assessment of liver function in patients with hepatocellular caicnoma: a new evidence-based approach - The ALBI Grade. Journal of Clinical Oncology, 33(6), 550-558. doi:10.1200/JCO.2014.57.9151DOI: 10.1200/JCO.2014.57.9151
Evaluation of a novel tissue stabilization gel to facilitate clinical sampling for translational research in surgical trials (Journal article)
Sutton, P. A., Jones, R. P., Morrison, F., Goldring, C. E., Park, B. K., Palmer, D. H., . . . Kitteringham, N. R. (2015). Evaluation of a novel tissue stabilization gel to facilitate clinical sampling for translational research in surgical trials. BRITISH JOURNAL OF SURGERY, 102(2), E124-E132. doi:10.1002/bjs.9678DOI: 10.1002/bjs.9678
Randomized phase II trial comparing the efficacy and safety of nintedanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC) (Conference Paper)
Palmer, D. H., Ma, Y. T., Peck-Radosavljevic, M., Ross, P. J., Graham, J. S., Fartoux, L., . . . Meyer, T. (2015). Randomized phase II trial comparing the efficacy and safety of nintedanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC). In JOURNAL OF CLINICAL ONCOLOGY Vol. 33. doi:10.1200/jco.2015.33.3_suppl.238DOI: 10.1200/jco.2015.33.3_suppl.238
2014
Hepatocellular carcinoma (Chapter)
Palmer, D. H., & Johnson, P. J. (2014). Hepatocellular carcinoma. In Treatment of Cancer (pp. 201-212). CRC Press. doi:10.1201/b17751-9DOI: 10.1201/b17751-9
Evolution in functionality of a metastatic pancreatic neuroendocrine tumour (pNET) causing Cushing's syndrome: treatment response with chemotherapy (Journal article)
Rajeev, S. P., McDougall, S., Terlizzo, M., Palmer, D., Daousi, C., & Cuthbertson, D. J. (2014). Evolution in functionality of a metastatic pancreatic neuroendocrine tumour (pNET) causing Cushing's syndrome: treatment response with chemotherapy. BMC ENDOCRINE DISORDERS, 14. doi:10.1186/1472-6823-14-70DOI: 10.1186/1472-6823-14-70
Chemotherapy, radiotherapy, chemoradiotherapy and combination therapy in localised and locally advanced pancreatic cancer (Journal article)
Sultana, A., Jackson, R. J., Cox, T., Palmer, D., Neoptolemos, J., & Ghaneh, P. (n.d.). Chemotherapy, radiotherapy, chemoradiotherapy and combination therapy in localised and locally advanced pancreatic cancer. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.cd011044DOI: 10.1002/14651858.cd011044
Assessment of liver dysfunction in hepatocellular carcinoma (HCC): An international collaborative study. (Conference Paper)
Johnson, P. J., Berhane, S., Kagebayashi, C., Satomura, S., Teng, M. J., Skowronska, A., . . . Kumada, T. (2014). Assessment of liver dysfunction in hepatocellular carcinoma (HCC): An international collaborative study.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32. doi:10.1200/jco.2014.32.15_suppl.4094DOI: 10.1200/jco.2014.32.15_suppl.4094
Proteomic analysis of primary colorectal cancer to generate response biomarkers for liver metastases (Conference Paper)
Sutton, P. A., Jones, R., Rowe, C., Jenkins, R., Malik, H. Z., Vimalachandran, D., . . . Palmer, D. H. (2014). Proteomic analysis of primary colorectal cancer to generate response biomarkers for liver metastases. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32. doi:10.1200/jco.2014.32.15_suppl.e14535DOI: 10.1200/jco.2014.32.15_suppl.e14535
Proteomic profiling of the diagnostic tumor biopsy to predict response to neoadjuvant chemoradiotherapy in rectal cancer (Conference Paper)
Sutton, P. A., Jones, R., Hamid, B., Abbott, G., Goldring, C., Palmer, D. H., . . . Vimalachandran, D. (2014). Proteomic profiling of the diagnostic tumor biopsy to predict response to neoadjuvant chemoradiotherapy in rectal cancer. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32. doi:10.1200/jco.2014.32.15_suppl.e14579DOI: 10.1200/jco.2014.32.15_suppl.e14579
Fas-associated factor (Faf1) is a novel CD40 interactor that regulates CD40-induced NF-kappa B activation via a negative feedback loop (Journal article)
Elmetwali, T., Young, L. S., & Palmer, D. H. (2014). Fas-associated factor (Faf1) is a novel CD40 interactor that regulates CD40-induced NF-kappa B activation via a negative feedback loop. CELL DEATH & DISEASE, 5. doi:10.1038/cddis.2014.172DOI: 10.1038/cddis.2014.172
Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. (Journal article)
Valle, J., Palmer, D., Jackson, R., Cox, T., Neoptolemos, J. P., Ghaneh, P., . . . Büchler, M. W. (2014). Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study.. Journal of Clinical Oncology, 32(6), 504-512. doi:10.1200/JCO.2013.50.7657DOI: 10.1200/JCO.2013.50.7657
Cardiopulmonary exercise testing before liver surgery (Journal article)
Dunne, D. F. J., Jones, R. P., Lythgoe, D. T., Pilkington, F. J., Palmer, D. H., Malik, H. Z., . . . Fenwick, S. W. (2014). Cardiopulmonary exercise testing before liver surgery. JOURNAL OF SURGICAL ONCOLOGY, 110(4), 439-444. doi:10.1002/jso.23670DOI: 10.1002/jso.23670
Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. (Journal article)
Greenhalf, W., Ghaneh, P., Neoptolemos, J. P., Palmer, D. H., Cox, T. F., Lamb, R. F., . . . Büchler, M. W. (2014). Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.. Journal of the National Cancer Institute, 106(1). doi:10.1093/jnci/djt347DOI: 10.1093/jnci/djt347
The ART strategy: Sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE (Journal article)
Yousuf, F., Cross, T. J. S., & Palmer, D. (2014). The ART strategy: Sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE. JOURNAL OF HEPATOLOGY, 61(1), 175. doi:10.1016/j.jhep.2014.02.032DOI: 10.1016/j.jhep.2014.02.032
The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers (Journal article)
Johnson, P. J., Pirrie, S. J., Cox, T. F., Berhane, S., Teng, M. J., Palmer, D. H., . . . Satomura, S. (2014). The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. Cancer Epidemiology, Biomarkers and Prevention, 23(1), 144-153. doi:10.1158/1055-9965.EPI-13-0870DOI: 10.1158/1055-9965.EPI-13-0870
2013
Chemotherapy induced hepatotoxicity in metastatic colorectal cancer: A review of mechanisms and outcomes (Journal article)
McWhirter, D., Kitteringham, N., Jones, R. P., Malik, H., Park, K., & Palmer, D. (2013). Chemotherapy induced hepatotoxicity in metastatic colorectal cancer: A review of mechanisms and outcomes. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 88(2), 404-415. doi:10.1016/j.critrevonc.2013.05.011DOI: 10.1016/j.critrevonc.2013.05.011
Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom (Journal article)
Palmer, D. H., Hussain, S. A., Smith, A. J., Hargreaves, S., Ma, Y. T., Hull, D., . . . Ross, P. J. (2013). Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom. BRITISH JOURNAL OF CANCER, 109(4), 888-890. doi:10.1038/bjc.2013.410DOI: 10.1038/bjc.2013.410
Radiofrequency Ablation With or Without Transcatheter Arterial Chemoembolization (Journal article)
Palmer, D. H. (2013). Radiofrequency Ablation With or Without Transcatheter Arterial Chemoembolization. JOURNAL OF CLINICAL ONCOLOGY, 31(21), 2756. doi:10.1200/JCO.2013.49.8352DOI: 10.1200/JCO.2013.49.8352
Peptide receptor radionuclide therapy with <SUP>90</SUP>Y-DOTATATE/<SUP>90</SUP>Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity (Journal article)
Vinjamuri, S., Gilbert, T. M., Banks, M., McKane, G., Maltby, P., Poston, G., . . . Cuthbertson, D. J. (2013). Peptide receptor radionuclide therapy with <SUP>90</SUP>Y-DOTATATE/<SUP>90</SUP>Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity. BRITISH JOURNAL OF CANCER, 108(7), 1440-1448. doi:10.1038/bjc.2013.103DOI: 10.1038/bjc.2013.103
Kadalayil, L., Benini, R., Pallan, L., O'Beirne, J., Marelli, L., Yu, D., . . . Meyer, T. (2013). A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer.. Annals of oncology : official journal of the European Society for Medical Oncology, 24(10), 2565-2570. doi:10.1093/annonc/mdt247DOI: 10.1093/annonc/mdt247
2012
Effect of Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid or Gemcitabine vs Observation on Survival in Patients With Resected Periampullary Adenocarcinoma The ESPAC-3 Periampullary Cancer Randomized Trial (Journal article)
Neoptolemos, J. P., Moore, M. J., Cox, T. F., Valle, J. W., Palmer, D. H., McDonald, A. C., . . . Buechler, M. W. (2012). Effect of Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid or Gemcitabine vs Observation on Survival in Patients With Resected Periampullary Adenocarcinoma The ESPAC-3 Periampullary Cancer Randomized Trial. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 308(2), 147-156. doi:10.1001/jama.2012.7352DOI: 10.1001/jama.2012.7352
A study of split-dose cisplatin-based neo-adjuvant chemotherapy in muscle-invasive bladder cancer (Journal article)
Hussain, S. A., Palmer, D. H., Lloyd, B., Collins, S. I., Barton, D., Ansari, J., & James, N. D. (2012). A study of split-dose cisplatin-based neo-adjuvant chemotherapy in muscle-invasive bladder cancer. ONCOLOGY LETTERS, 3(4), 855-859. doi:10.3892/ol.2012.563DOI: 10.3892/ol.2012.563
A multicentre, open label, phase I study to evaluate safety and pharmacokinetics of BIBF 1120 for patients with advanced hepatocellular carcinoma (Journal article)
Palmer, D. H., Loembe, A. B., Studeny, M., & Meyer, T. (2012). A multicentre, open label, phase I study to evaluate safety and pharmacokinetics of BIBF 1120 for patients with advanced hepatocellular carcinoma.
Fas-associated Factor 1 (FAF1) is a novel CD40 interactor that contributes to NFkappaB regulation via a negative feedback loop (Journal article)
Elmetwali, T., Young, L. S., & Palmer, D. H. (2012). Fas-associated Factor 1 (FAF1) is a novel CD40 interactor that contributes to NFkappaB regulation via a negative feedback loop.
2011
Cytotoxic Chemotherapy and Endocrine Therapy for Hepatocellular Carcinoma (Chapter)
Palmer, D., & Johnson, P. J. (2011). Cytotoxic Chemotherapy and Endocrine Therapy for Hepatocellular Carcinoma. In Hepatocellular Carcinoma: (pp. 337-353). Springer New York. doi:10.1007/978-1-60327-522-4_21DOI: 10.1007/978-1-60327-522-4_21
2010
Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection A Randomized Controlled Trial (Journal article)
Neoptolemos, J. P., Stocken, D. D., Bassi, C., Ghaneh, P., Cunningham, D., Goldstein, D., . . . Buechler, M. W. (2010). Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection A Randomized Controlled Trial. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 304(10), 1073-1081. doi:10.1001/jama.2010.1275DOI: 10.1001/jama.2010.1275
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. (Journal article)
Valle, J., Wasan, H., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A., . . . ABC-02 Trial Investigators. (2010). Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.. The New England journal of medicine, 362(14), 1273-1281. doi:10.1056/nejmoa0908721DOI: 10.1056/nejmoa0908721
Elmetwali, T., Searle, P. F., McNeish, I., Young, L. S., & Palmer, D. H. (2010). CD40 ligand induced cytotoxicity in carcinoma cells is enhanced by inhibition of metalloproteinase cleavage and delivery via a conditionally-replicating adenovirus.. Molecular cancer, 9, 52. doi:10.1186/1476-4598-9-52DOI: 10.1186/1476-4598-9-52
A phase Ib/IIa trial to evaluate the CCK2 receptor antagonist Z-360 in combination with gemcitabine in patients with advanced pancreatic cancer. (Journal article)
Meyer, T., Caplin, M. E., Palmer, D. H., Valle, J. W., Larvin, M., Waters, J. S., . . . Kato, H. (2010). A phase Ib/IIa trial to evaluate the CCK2 receptor antagonist Z-360 in combination with gemcitabine in patients with advanced pancreatic cancer.. European journal of cancer (Oxford, England : 1990), 46(3), 526-533. doi:10.1016/j.ejca.2009.11.004DOI: 10.1016/j.ejca.2009.11.004
CD40 ligand-induced carcinoma cell death: a balance between activation of TNFR-associated factor (TRAF) 3-dependent death signals and suppression of TRAF6-dependent survival signals. (Journal article)
Elmetwali, T., Young, L. S., & Palmer, D. H. (2010). CD40 ligand-induced carcinoma cell death: a balance between activation of TNFR-associated factor (TRAF) 3-dependent death signals and suppression of TRAF6-dependent survival signals.. Journal of immunology (Baltimore, Md. : 1950), 184(2), 1111-1120. doi:10.4049/jimmunol.0900528DOI: 10.4049/jimmunol.0900528
2009
Role of Tyrosine Kinase Inhibitors in Lung Cancer (Journal article)
Ansari, J., Palmer, D. H., Rea, D. W., & Hussain, S. A. (2009). Role of Tyrosine Kinase Inhibitors in Lung Cancer. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 9(5), 569-575. doi:10.2174/187152009788451879DOI: 10.2174/187152009788451879
A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. (Journal article)
Palmer, D. H., Midgley, R. S., Mirza, N., Torr, E. E., Ahmed, F., Steele, J. C., . . . Adams, D. H. (2009). A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma.. Hepatology (Baltimore, Md.), 49(1), 124-132. doi:10.1002/hep.22626DOI: 10.1002/hep.22626
2008
The clinical management of hepatic neoplasms (Chapter)
Palmer, D., & Johnson, P. (2008). The clinical management of hepatic neoplasms. In Interventional Radiological Treatment of Liver Tumors (pp. 1-24). Cambridge University Press. doi:10.1017/cbo9780511575433.003DOI: 10.1017/cbo9780511575433.003
Biology of testicular germ cell tumors (Journal article)
Hussain, S. A., Ma, Y. T., Palmer, D. H., Hutton, P., & Cullen, M. H. (2008). Biology of testicular germ cell tumors. EXPERT REVIEW OF ANTICANCER THERAPY, 8(10), 1659-1673. doi:10.1586/14737140.8.10.1659DOI: 10.1586/14737140.8.10.1659
Hepatocellular Carcinoma: Medical Management (Chapter)
Johnson, P., & Palmer, D. (2008). Hepatocellular Carcinoma: Medical Management. In Interventional Oncology (pp. 115-120). Cambridge University Press. doi:10.1017/cbo9780511722226.012DOI: 10.1017/cbo9780511722226.012
Neoadjuvant Chemotherapy in Resectable Pancreatic Cancer (Journal article)
Palmer, D. H., Stocken, D. D., Hewitt, H., Markham, C. E., Hassan, A. B., Johnson, P. J., . . . Bramhall, S. R. (2008). Neoadjuvant Chemotherapy in Resectable Pancreatic Cancer. Annals of Surgical Oncology, 15(7), 2061. doi:10.1245/s10434-008-9921-2DOI: 10.1245/s10434-008-9921-2
Liver (Chapter)
Liver (2008). In Treatment of Cancer (pp. 583-596). CRC Press. doi:10.1201/b13550-29DOI: 10.1201/b13550-29
Genomics and Pharmacogenomics in the Management of Breast Cancer (Journal article)
Hussain, S., Pascoe, J., Palmer, D., Spooner, D., & Rea, D. (2008). Genomics and Pharmacogenomics in the Management of Breast Cancer. Current Pharmacogenomics and Personalized Medicine, 6(1), 45-55. doi:10.2174/187569208784017485DOI: 10.2174/187569208784017485
A phase II clinical trial of gemcitabine and split dose cisplatin in advanced non-small cell lung cancer in an outpatient setting (Journal article)
Hussain, S. A., Palmer, D. H., Swinson, D. E., Riley, P., Wills, A., Brown, C., . . . Cullen, M. H. (2008). A phase II clinical trial of gemcitabine and split dose cisplatin in advanced non-small cell lung cancer in an outpatient setting. ONCOLOGY REPORTS, 20(1), 233-237. Retrieved from https://www.webofscience.com/
2007
New medical options for liver tumours. (Journal article)
Williams, S., Palmer, D., & Johnson, P. (2007). New medical options for liver tumours.. Clinical medicine (London, England), 7(4), 351-356. doi:10.7861/clinmedicine.7-4-351DOI: 10.7861/clinmedicine.7-4-351
Molecularly targeted therapeutics for breast cancer (Journal article)
Hussain, S. A., Palmer, D. H., Spooner, D., & Rea, D. W. (2007). Molecularly targeted therapeutics for breast cancer. BIODRUGS, 21(4), 215-224. doi:10.2165/00063030-200721040-00002DOI: 10.2165/00063030-200721040-00002
A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. (Journal article)
Palmer, D. H., Stocken, D. D., Hewitt, H., Markham, C. E., Hassan, A. B., Johnson, P. J., . . . Bramhall, S. R. (2007). A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin.. Annals of surgical oncology, 14(7), 2088-2096. doi:10.1245/s10434-007-9384-xDOI: 10.1245/s10434-007-9384-x
Reply: Randomised studies with translational end points are required to further elucidate the prognostic and predictive value of CA IX (Journal article)
Hussain, S. A., Rea, D. W., & Palmer, D. H. (2007). Reply: Randomised studies with translational end points are required to further elucidate the prognostic and predictive value of CA IX. BRITISH JOURNAL OF CANCER, 96(8), 1310. doi:10.1038/sj.bjc.6603716DOI: 10.1038/sj.bjc.6603716
Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer (Journal article)
Hussain, S. A., Ganesan, R., Reynolds, G., Gross, L., Stevens, A., Pastorek, J., . . . Palmer, D. H. (2007). Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer. BRITISH JOURNAL OF CANCER, 96(1), 104-109. doi:10.1038/sj.bjc.6603530DOI: 10.1038/sj.bjc.6603530
Signal transduction therapy: Challenges to clinical trial design (Journal article)
Hussain, S. A., Rea, D. W., James, N. D., & Palmer, D. H. (2007). Signal transduction therapy: Challenges to clinical trial design. CURRENT SIGNAL TRANSDUCTION THERAPY, 2(1), 21-30. doi:10.2174/157436207779317137DOI: 10.2174/157436207779317137
2005
Role of chemotherapy in breast cancer (Journal article)
Hussain, S. A., Palmer, D. H., Stevens, A., Spooner, D., Poole, C. J., & Rea, D. W. (2005). Role of chemotherapy in breast cancer. EXPERT REVIEW OF ANTICANCER THERAPY, 5(6), 1095-1110. doi:10.1586/14737140.5.6.1095DOI: 10.1586/14737140.5.6.1095
Gene- and immunotherapy for hepatocellular carcinoma (Journal article)
Palmer, D. H., Hussain, S. A., & Johnson, P. J. (2005). Gene- and immunotherapy for hepatocellular carcinoma. EXPERT OPINION ON BIOLOGICAL THERAPY, 5(4), 507-523. doi:10.1517/14712598.5.4.507DOI: 10.1517/14712598.5.4.507
Pre-operative locoregional therapy and liver transplantation for hepatocellular carcinoma: time for a randomized controlled trial. (Journal article)
Palmer, D. H., & Johnson, P. J. (2005). Pre-operative locoregional therapy and liver transplantation for hepatocellular carcinoma: time for a randomized controlled trial.. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 5(4 Pt 1), 641-642. doi:10.1111/j.1600-6143.2005.00856.xDOI: 10.1111/j.1600-6143.2005.00856.x
2004
Systemic therapies for hepatocellular carcinoma (Journal article)
Palmer, D. H., Hussain, S. A., & Johnson, P. J. (2004). Systemic therapies for hepatocellular carcinoma. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 13(12), 1555-1568. doi:10.1517/13543784.13.12.1555DOI: 10.1517/13543784.13.12.1555
A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer (Journal article)
Hussain, S. A., Stocken, D. D., Riley, P., Palmer, D. H., Peake, D. R., Geh, J. I., . . . James, N. D. (2004). A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer. BRITISH JOURNAL OF CANCER, 91(5), 844-849. doi:10.1038/sj.bjc.6602112DOI: 10.1038/sj.bjc.6602112
CD40 expression in prostate cancer: A potential diagnostic and therapeutic molecule (Journal article)
Palmer, D. H., Hussain, S. A., Ganesan, R., Cooke, P. W., Wallace, D. M. A., Young, L. S., & James, N. D. (2004). CD40 expression in prostate cancer: A potential diagnostic and therapeutic molecule. ONCOLOGY REPORTS, 12(4), 679-682. Retrieved from https://www.webofscience.com/
Carbonic anhydrase IX, a marker of hypoxia: Correlation with clinical outcome in transitional cell carcinoma of the bladder (Journal article)
Hussain, S. A., Palmer, D. H., Ganesan, R., Hiller, L., Gregory, J., Murray, P. G., . . . James, N. D. (2004). Carbonic anhydrase IX, a marker of hypoxia: Correlation with clinical outcome in transitional cell carcinoma of the bladder. ONCOLOGY REPORTS, 11(5), 1005-1010. Retrieved from https://www.webofscience.com/
Endocrine therapy and other targeted therapies for metastatic breast cancer. (Journal article)
Hussain, S. A., Palmer, D. H., Moon, S., & Rea, D. W. (2004). Endocrine therapy and other targeted therapies for metastatic breast cancer.. Expert review of anticancer therapy, 4(6), 1179-1195. doi:10.1586/14737140.4.6.1179DOI: 10.1586/14737140.4.6.1179
2001
Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: A phase I and pharmacokinetic study of its prodrug, CB1954 (Journal article)
Chung-Faye, G., Palmer, D., Anderson, D., Clark, J., Downes, M., Baddeley, J., . . . Kerr, D. J. (2001). Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: A phase I and pharmacokinetic study of its prodrug, CB1954. CLINICAL CANCER RESEARCH, 7(9), 2662-2668. Retrieved from https://www.webofscience.com/
